• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Abcam plc

    10/16/23 8:00:13 AM ET
    $ABCM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ABCM alert in real time by email
    SC 13D 1 p23-2597sc13d.htm

     

     

    UNITED STATES  
    SECURITIES AND EXCHANGE COMMISSION  
    Washington, D.C. 20549  
     
    SCHEDULE 13D
     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    Abcam plc

    (Name of Issuer)
     

    Ordinary shares, nominal value £0.002 per share

    (Title of Class of Securities)
     

    000380204**

    (CUSIP Number)
     

    Jon L. Mosle

    HBK Investments L.P.

    2300 North Field Street, Suite 2200

    Dallas, Texas 75201

    (214) 758-6107

     
    Eleazer Klein, Esq.
    Adriana Schwartz, Esq.
    Schulte Roth & Zabel LLP
    919 Third Avenue
    New York, NY 10022

    (212) 756-2000

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     

    October 12, 2023

    (Date of Event which Requires Filing of this Schedule)
     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(c), 13d-1(f) or 13d-1(g), check the following box. [ ]

     

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

    (Page 1 of 22 Pages)

    ______________________________

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    ** There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 000380204 has been assigned to the American Depositary Shares (“ADSs”) of the Issuer, which are quoted on The NASDAQ Global Select Market under the symbol “ABCM.” Each ADS represents 1 Ordinary Share.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 000380204SCHEDULE 13DPage 2 of 22 Pages

     

    1

    NAME OF REPORTING PERSON

    HBK Investments L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(c) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

    - 0 -

    8

    SHARED VOTING POWER

    17,270,000 ordinary shares (represented by 17,270,000 ADSs)

    9

    SOLE DISPOSITIVE POWER

    - 0 -

    10

    SHARED DISPOSITIVE POWER

    17,270,000 ordinary shares (represented by 17,270,000 ADSs)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    17,270,000 ordinary shares (represented by 17,270,000 ADSs)

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    7.5%

    14

    TYPE OF REPORTING PERSON

    IA, PN

             

     

     

    CUSIP No. 000380204SCHEDULE 13DPage 3 of 22 Pages

     

    1

    NAME OF REPORTING PERSON

    HBK Services LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(c) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

    - 0 -

    8

    SHARED VOTING POWER

    17,270,000 ordinary shares (represented by 17,270,000 ADSs)

    9

    SOLE DISPOSITIVE POWER

    - 0 -

    10

    SHARED DISPOSITIVE POWER

    17,270,000 ordinary shares (represented by 17,270,000 ADSs)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    17,270,000 ordinary shares (represented by 17,270,000 ADSs)

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    7.5%

    14

    TYPE OF REPORTING PERSON

    IA, OO

             

     

    CUSIP No. 000380204SCHEDULE 13DPage 4 of 22 Pages

     

    1

    NAME OF REPORTING PERSON

    HBK Management LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(c) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

    - 0 -

    8

    SHARED VOTING POWER

    17,270,000 ordinary shares (represented by 17,270,000 ADSs)

    9

    SOLE DISPOSITIVE POWER

    - 0 -

    10

    SHARED DISPOSITIVE POWER

    17,270,000 ordinary shares (represented by 17,270,000 ADSs)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    17,270,000 ordinary shares (represented by 17,270,000 ADSs)

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    7.5%

    14

    TYPE OF REPORTING PERSON

    HC, OO

             

     

    CUSIP No. 000380204SCHEDULE 13DPage 5 of 22 Pages

     

     

    1

    NAME OF REPORTING PERSON

    HBK Capital Ltd.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(c) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

    - 0 -

    8

    SHARED VOTING POWER

    17,270,000 ordinary shares (represented by 17,270,000 ADSs)

    9

    SOLE DISPOSITIVE POWER

    - 0 -

    10

    SHARED DISPOSITIVE POWER

    17,270,000 ordinary shares (represented by 17,270,000 ADSs)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    17,270,000 ordinary shares (represented by 17,270,000 ADSs)

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    7.5%

    14

    TYPE OF REPORTING PERSON

    OO

             

     

     

    CUSIP No. 000380204SCHEDULE 13DPage 6 of 22 Pages

     

     

    1

    NAME OF REPORTING PERSON

    HBK Master Fund L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    WC

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(c) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

    - 0 -

    8

    SHARED VOTING POWER

    7,998,329 ordinary shares (represented by 7,998,329 ADSs)

    9

    SOLE DISPOSITIVE POWER

    - 0 -

    10

    SHARED DISPOSITIVE POWER

    7,998,329 ordinary shares (represented by 7,998,329 ADSs)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    7,998,329 ordinary shares (represented by 7,998,329 ADSs)

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    3.5%

    14

    TYPE OF REPORTING PERSON

    PN

             

     

    CUSIP No. 000380204SCHEDULE 13DPage 7 of 22 Pages

     

     

    1

    NAME OF REPORTING PERSON

    HBK Merger Strategies Master Fund L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    WC

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(c) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

    - 0 -

    8

    SHARED VOTING POWER

    9,271,671 ordinary shares (represented by 9,271,671 ADSs)

    9

    SOLE DISPOSITIVE POWER

    - 0 -

    10

    SHARED DISPOSITIVE POWER

    9,271,671 ordinary shares (represented by 9,271,671 ADSs)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    9,271,671 ordinary shares (represented by 9,271,671 ADSs)

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    4.0%

    14

    TYPE OF REPORTING PERSON

    PN

             

     

    CUSIP No. 000380204SCHEDULE 13DPage 8 of 22 Pages

     

     

    Item 1. SECURITY AND ISSUER

     

      This statement on Schedule 13D (the “Schedule 13D”) relates to the ordinary shares, par value £0.002 per share (the “Ordinary Shares”), of Abcam plc, a corporation incorporated under the laws of the United Kingdom (the “Issuer”). The principal executive offices of the Issuer are located at Discovery Drive, Cambridge Biomedical Campus, Cambridge, CB2 0AX, United Kingdom.

     

    Item 2. IDENTITY AND BACKGROUND.

     

    (a) This Schedule 13D is being filed by: (i) HBK Investments L.P., a Delaware limited partnership (“HBK Investments”); (ii) HBK Services LLC, a Delaware limited liability company (“HBK Services”); (iii) HBK Management LLC, a Delaware limited liability company (“HBK Management”); (iv) HBK Capital Ltd., a Cayman Islands exempted company (“HBK Capital”); (v) HBK Master Fund L.P., a Cayman Islands exempted limited partnership (“HBK Master”); and (vi) HBK Merger Strategies Master Fund L.P., a Cayman Islands exempted limited partnership (“HBK Merger”, and together with HBK Investments, HBK Services, HBK Management, HBK Capital and HBK Master, the “Reporting Persons”).

     

      The Reporting Persons are making a single, joint filing on Schedule 13D. The agreement among the Reporting Persons to file jointly (the “Joint Filing Agreement”) is attached hereto as Exhibit 99.1.  Each Reporting Person disclaims beneficial ownership of all ADSs representing the Ordinary Shares, other than those reported herein as being owned by it.

     

     

    HBK Master is the holder of the ADSs representing Ordinary Shares listed on its cover page hereto. HBK Capital serves as the general partner of HBK Master. HBK Master and HBK Capital have delegated to HBK Investments discretion to vote and dispose of the ADSs held by HBK Master. 

     

      HBK Merger is the holder of the ADSs representing Ordinary Shares listed on its cover page hereto.  HBK Capital serves as the general partner of HBK Merger.  HBK Merger and HBK Capital have delegated to HBK Investments discretion to vote and dispose of the ADSs held by HBK Merger.

     

      HBK Management serves as the general partner of HBK Investments.

     

      HBK Investments has delegated discretion to vote and dispose of the ADSs held by HBK Master and HBK Merger to HBK Services.  HBK Services may, from time to time, delegate investment discretion to vote and dispose of certain ADSs held by HBK Master or HBK Merger to HBK New York LLC, a Delaware limited liability company, HBK Virginia LLC, a Delaware limited liability company or HBK Europe Management LLP, a limited liability partnership organized under the laws of the United Kingdom (collectively, the “Subadvisors”).  Each of HBK Services and the Subadvisors is under common control with HBK Investments.  The Subadvisors do not own any ADSs or Ordinary Shares directly and disclaim beneficial ownership of the Ordinary Shares represented by ADSs held by HBK Master and HBK Merger.

     

     

    CUSIP No. 000380204SCHEDULE 13DPage 9 of 22 Pages

     

     

     

    Each Reporting Person declares that neither the filing of this Schedule 13D nor anything herein shall be construed as an admission that such person is or was, for the purposes of Section 13(d) or 13(g) of the Act, the beneficial owner of any Ordinary Shares. The Subadvisors declare that neither the filing of this Schedule 13D nor anything herein shall be construed as an admission that they are or were, for the purposes of Section 13(d) or 13(g) of the Act, beneficial owners of any Ordinary Shares.

     

    (b) The principal business address of each of the Reporting Persons is 2300 North Field Street, Suite 2200, Dallas, Texas 75201.

     

    (c) HBK Master and HBK Merger are private investment funds. HBK Investments is an investment management firm that provides investment management services to private investment funds. HBK Services is an investment management firm. HBK Capital Management Group L.P., a Delaware limited partnership (“HBK Capital Group”), is the sole member of HBK Services. HBK Management is the general partner of HBK Investments and HBK Capital Group. HBK Capital serves as the general partner of HBK Master and HBK Merger.  

     

    (d) No Reporting Person has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e) No Reporting Person has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f)

    HBK Investments is a Delaware limited partnership. HBK Services is a Delaware limited liability company. HBK Management is a Delaware limited liability company. HBK Capital is a Cayman Islands exempted company. HBK Master and HBK Merger are Cayman Islands exempted limited partnerships.

     

    Schedule A attached hereto sets forth the information required by Instruction C of the instructions to Schedule 13D.

     

    Item 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

     

      The ADSs representing the Ordinary Shares reported herein are held by HBK Master and HBK Merger. Funds to purchase the ADSs were derived from general working capital and margin account borrowings made in the ordinary course of business as and when required to open or carry positions in the margin account, subject to applicable federal margin regulations, stock exchange rules and credit policies.  In such instances, the positions held in the margin account are pledged as collateral security for the repayment of debit balances in the account.  The margin account may from time to time have debit balances. Since other securities are held in the margin account, it is not possible to determine the amounts, if any, of margin used to purchase the ADSs representing the Ordinary Shares reported herein.  A total of approximately $391,905,897 was paid to acquire the ADSs representing the Ordinary Shares reported herein.

     

     

    CUSIP No. 000380204SCHEDULE 13DPage 10 of 22 Pages

     

     

    Item 4. PURPOSE OF TRANSACTION.

     

     

    Each of HBK Master and HBK Merger acquired the ADSs reported herein for investment purposes in the ordinary course of its business, pursuant to investment strategies, including merger arbitrage and event driven strategies, because the Reporting Persons believed, among other things, that the ADSs, when purchased, represented an attractive investment opportunity.

    The Reporting Persons intend to vote in favor of the proposed sale of the Issuer to Danaher Corporation for $24.00 per share in cash (the “Proposed Transaction”). The Reporting Persons believe that the Proposed Transaction was achieved as a result of a rigorous process undertaken by the board of directors of the Issuer and that a vote failure would create significant risks for the business going forward.

    The Reporting Persons intend to review their investment in the Issuer on a continuing basis. While the Reporting Persons have no current intention to do so, depending on future events or circumstances, the Reporting Persons could in the future engage in discussions with management, the board of directors, other shareholders of the Issuer and other relevant parties concerning the business, operations, management, governance, strategy and future plans of the Issuer, including the Proposed Transaction.  Depending on various factors including, without limitation, the terms and status of the Proposed Transaction and any developments related thereto, the Issuer’s financial position and strategic direction, actions taken by the board of directors, price levels of the ADSs, other investment opportunities available to the Reporting Persons, conditions in the securities markets and general economic, geopolitical and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without limitation, (i) increasing or decreasing their position in the Issuer through, among other things, the purchase or sale of securities of the Issuer, including through transactions involving the ADSs or Ordinary Shares and/or other equity, debt, notes, other securities, or derivative or other instruments that are based upon or relate to the value of securities of the Issuer in the open market or in private transactions, and/or (ii) entering into transactions that increase or hedge their economic exposure to the ADSs and/or Ordinary Shares without affecting their beneficial ownership of the Ordinary Shares.  The Reporting Persons may, at any time and from time to time, review or reconsider their position and/or change their intentions and/or formulate plans or proposals with respect to their investment in the Issuer, including as related to the Proposed Transaction. 

    Except as set forth herein or as would occur upon completion of any of the actions discussed herein, the Reporting Persons have no present plan or proposal that would relate to or result in any of the matters set forth in subparagraphs (a)-(j) of Item 4 of Schedule 13D.

     

    Item 5. INTEREST IN SECURITIES OF THE COMPANY.

     

    (a) See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of Ordinary Shares and percentages of the Ordinary Shares beneficially owned by each Reporting Person.  The aggregate percentage of Ordinary Shares reported to be beneficially owned by each Reporting Person is based upon 230,151,118 Ordinary Shares outstanding as of October 2, 2023, as reported in Exhibit 99.2 to the Issuer’s Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission on October 5, 2023.

     

     

    CUSIP No. 000380204SCHEDULE 13DPage 11 of 22 Pages

     

     

    (b) See rows (7) through (10) of the cover pages to this Schedule 13D for the number of Ordinary Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.

     

    (c) Information concerning transactions in the ADSs by the Reporting Persons during the past sixty (60) days is set forth in Schedule B hereto.  No Reporting Person has transacted directly in the Ordinary Shares during the past sixty (60) days.

     

    (d) No person other than the Reporting Persons is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the ADSs held by HBK Master and HBK Merger.

     

    (e) Not applicable.

     

    Item 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.

     

      Except for the Joint Filing Agreement, the Reporting Persons do not have any contract, arrangement, understanding or relationship with any person with respect to the securities of the Issuer.

     

    Item 7. MATERIAL TO BE FILED AS EXHIBITS.

     

    Exhibit 99.1  Joint Filing Agreement.

     

    CUSIP No. 000380204SCHEDULE 13DPage 12 of 22 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: October 16, 2023

     

      HBK INVESTMENTS L.P.
         
      By: /s/ Jon L. Mosle
        Name:  Jon L. Mosle
        Title:  Authorized Signatory

     

      HBK Services LLC
         
      By: /s/ Jon L. Mosle
        Name:  Jon L. Mosle
        Title:  Authorized Signatory

     

      HBK MANAGEMENT LLC
         
      By: /s/ Jon L. Mosle
        Name:  Jon L. Mosle
        Title:  Authorized Signatory

     

      HBK CAPITAL LTD.
         
      By: /s/ Jon L. Mosle
        Name:  Jon L. Mosle
        Title:  Authorized Signatory

     

      HBK MASTER FUND L.P.
      By: HBK Services LLC, its investment advisor
         
      By: /s/ Jon L. Mosle
        Name:  Jon L. Mosle
        Title:  Authorized Signatory

     

      HBK MERGER STRATEGIES MASTER FUND L.P.
      By: HBK Services LLC, its investment advisor
         
      By: /s/ Jon L. Mosle
        Name:  Jon L. Mosle
        Title:  Authorized Signatory

     

    CUSIP No. 000380204SCHEDULE 13DPage 13 of 22 Pages

    Schedule A

     

    GENERAL PARTNERS, CONTROL PERSONS, DIRECTORS AND EXECUTIVE OFFICERS OF CERTAIN REPORTING PERSONS

     

    The following sets forth the name, position, address, principal occupation and citizenship of each general partner, control person, director and/or executive officer of the applicable Reporting Persons (the “Instruction C Persons”). To the best of the Reporting Persons’ knowledge, (i) none of the Instruction C Persons during the last five years has been convicted in a criminal proceeding (excluding traffic violations or other similar misdemeanors) or been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws and (ii) none of the Instruction C Persons beneficially owns any Ordinary Shares or is party to any contract or agreement as would require disclosure in this Schedule 13D.

     

    REPORTING PERSON: HBK MANAGEMENT LLC AND HBK CAPITAL LTD.

     

    Jamiel A. Akhtar (“Mr. Akhtar”) is a member of HBK Management and serves as a director of HBK Capital. His business address is c/o HBK Investments L.P., 2300 North Field Street, Suite 2200, Dallas, Texas 75201. His principal occupation is acting as Managing Director and Co-Chief Investment Officer of HBK Investments. Mr. Akhtar is a United States citizen.

     

    Jon L. Mosle (“Mr. Mosle”) is a member of HBK Management and serves as a director of HBK Capital. His business address is c/o HBK Investments L.P., 2300 North Field Street, Suite 2200, Dallas, Texas 75201. His principal occupation is acting as Managing Director and President of HBK Investments. Mr. Mosle is a United States citizen.

     

    Matthew F. Luth (“Mr. Luth”) is a member of HBK Management and serves as a director of HBK Capital. His business address is c/o HBK Investments L.P., 2300 North Field Street, Suite 2200, Dallas, Texas 75201. His principal occupation is acting as Managing Director and Co-Chief Investment Officer of HBK Investments. Mr. Luth is a United States citizen.

     

     

    CUSIP No. 000380204SCHEDULE 13DPage 14 of 22 Pages

     

    Schedule B

     

    Transactions in the ADSs of the Issuer by the Reporting Persons During the Past Sixty (60) Days

     

    The following table sets forth all transactions in the ADSs effected during the past sixty (60) days by the Reporting Persons. Except as noted below, all such transactions were effected in the open market through brokers and the price per ADS excludes commissions.

    HBK Master

     

    Trade Date

    ADSs Purchased

    (Sold)

    Price Per ADS ($)
    8/28/2023 41,148 22.638900
    8/28/2023 279,404 22.598600
    8/28/2023 23,284 22.615000
    8/28/2023 69,851 22.604500
    8/28/2023 46,568 22.595000
    8/28/2023 23,284 22.600000
    8/28/2023 46,568 22.607500
    8/28/2023 23,284 22.629400
    8/28/2023 46,567 22.542500
    8/28/2023 81,493 22.518100
    8/28/2023 93,133 22.449400
    8/28/2023 69,851 22.450100
    8/28/2023 81,492 22.452000
    8/29/2023 271,283 22.502400
    8/29/2023 128,740 22.626100
    8/29/2023 16,732 22.509800
    8/29/2023 23,148 22.485000
    8/29/2023 277,778 22.653200

     

     

     

    CUSIP No. 000380204SCHEDULE 13DPage 15 of 22 Pages

     

     

    Trade Date

    ADSs Purchased

    (Sold)

    Price Per ADS ($)
    8/29/2023 57,870 22.634400
    8/29/2023 46,296 22.642300
    8/29/2023 208,331 22.658700
    8/29/2023 23,060 22.678300
    8/29/2023 46,296 22.660000
    8/29/2023 92,592 22.667600
    8/29/2023 46,296 22.635000
    8/29/2023 46,296 22.632500
    8/29/2023 34,722 22.612300
    8/29/2023 23,148 22.619000
    8/29/2023 11,574 22.600000
    8/29/2023 81,018 22.671200
    8/29/2023 11,574 22.659600
    8/29/2023 23,148 22.674500
    8/29/2023 11,574 22.705500
    8/29/2023 138,891 22.684300
    8/30/2023 104,167 22.604100
    8/30/2023 52,057 22.646500
    8/30/2023 273,037 22.500000
    8/30/2023 79,999 22.631700
    8/30/2023 115,740 22.609400
    8/30/2023 46,298 22.592500
    8/30/2023 23,149 22.621500
    8/31/2023 69,444 22.603000

     

     

     

    CUSIP No. 000380204SCHEDULE 13DPage 16 of 22 Pages

     

     

    Trade Date

    ADSs Purchased

    (Sold)

     

    Price Per ADS ($)
    8/31/2023 75,997 22.600000
    8/31/2023 76,657 22.599900
    9/1/2023 46 22.630000
    9/5/2023 11,651 22.819900
    9/5/2023 34,722 22.863300
    9/5/2023 23,148 22.817800
    9/5/2023 4,630 22.860700
    9/5/2023 4,630 22.859100
    9/5/2023 23,906 22.890300
    9/5/2023 23,148 22.850000
    9/6/2023 59,427 22.847200
    9/6/2023 46,296 22.816100
    9/6/2023 111,216 22.763400
    9/6/2023 23,148 22.849900
    9/6/2023 46,296 22.820200
    9/6/2023 23,148 22.789000
    9/6/2023 34,722 22.790600
    9/6/2023 9,259 22.830000
    9/7/2023 16,098 22.850000
    9/7/2023 46,296 22.869600
    9/7/2023 57,870 22.879500
    9/7/2023 69,444 22.871600
    9/7/2023 23,148 22.859400
    9/7/2023 46,296 22.865000

     

     

     

    CUSIP No. 000380204SCHEDULE 13DPage 17 of 22 Pages

     

     

    Trade Date

    ADSs Purchased

    (Sold)

    Price Per ADS ($)
    9/7/2023 23,148 22.850000
    9/7/2023 34,722 22.860300
    9/7/2023 23,148 22.862800
    9/7/2023 7,453 22.830000
    9/8/2023 15,696 22.860000
    9/11/2023 23,149 22.800000
    9/11/2023 72,141 22.770900
    9/11/2023 127,348 22.784700
    9/11/2023 20,833 22.801700
    9/11/2023 11,574 22.789400
    9/12/2023 13,476 22.750000
    9/12/2023 23,149 22.730200
    9/12/2023 23,149 22.734800
    9/12/2023 9,260 22.717400
    9/12/2023 95,321 22.750000
    9/13/2023 11,160 22.720000
    9/13/2023 46,296 22.691600
    9/13/2023 1,407 22.700000
    9/13/2023 847 22.710000
    9/15/2023 23,148 22.670000
    9/15/2023 20,893 22.660700
    9/15/2023 32,407 22.652500
    9/15/2023 115,742 22.650000

     

     

     

    CUSIP No. 000380204SCHEDULE 13DPage 18 of 22 Pages

     

    Trade Date

    ADSs Purchased

    (Sold) 

    Price Per ADS ($)
    9/18/2023 23,148 22.640000
    9/18/2023 36,162 22.645800
    9/18/2023 11,574 22.654000
    9/18/2023 57,870 22.650000
    9/19/2023 10,136 22.639700
    10/4/2023 23,148 22.798800
    10/5/2023 69,444 22.829900
    10/6/2023 23,148 22.706100
    10/12/2023 144,907 22.741800
    10/12/2023 1,094,907 22.741800
    10/12/2023 46,296 22.709000
    10/13/2023 69,444 22.700000
    10/13/2023 32,407 22.730000
    10/13/2023 23,148 22.690000
    10/13/2023 1,500,646 22.710000

     

     

    HBK Merger

     

    Trade Date

    ADSs Purchased

    (Sold)

    Price Per ADS ($)
    8/28/2023 58,852 22.638900
    8/28/2023 320,596 22.598600
    8/28/2023 26,716 22.615000
    8/28/2023 80,149 22.604500
    8/28/2023 53,432 22.595000
    8/28/2023 26,716 22.600000
    8/28/2023 53,432 22.607500
    8/28/2023 26,716 22.629400
    8/28/2023 53,433 22.542500
    8/28/2023 93,507 22.518100
    8/28/2023 106,867 22.449400
    8/28/2023 80,149 22.450100

     

     

    CUSIP No. 000380204SCHEDULE 13DPage 19 of 22 Pages

     

     

    Trade Date

    ADSs Purchased

    (Sold)

    Price Per ADS ($)
    8/28/2023 93,508 22.452000
    8/29/2023 314,687 22.502400
    8/29/2023 149,339 22.626100
    8/29/2023 19,409 22.509800
    8/29/2023 26,852 22.485000
    8/29/2023 322,222 22.653200
    8/29/2023 67,130 22.634400
    8/29/2023 53,704 22.642300
    8/29/2023 241,669 22.658700
    8/29/2023 26,750 22.678300
    8/29/2023 53,704 22.660000
    8/29/2023 107,408 22.667600
    8/29/2023 53,704 22.635000
    8/29/2023 53,704 22.632500
    8/29/2023 40,278 22.612300
    8/29/2023 26,852 22.619000
    8/29/2023 13,426 22.600000
    8/29/2023 93,982 22.671200
    8/29/2023 13,426 22.659600
    8/29/2023 26,852 22.674500
    8/29/2023 13,426 22.705500
    8/29/2023 161,109 22.684300
    8/30/2023 120,833 22.604100
    8/30/2023 60,387 22.646500

     

     

     

    CUSIP No. 000380204SCHEDULE 13DPage 20 of 22 Pages

     

     

    Trade Date

    ADSs Purchased

    (Sold)

    Price Per ADS ($)
    8/30/2023 316,721 22.500000
    8/30/2023 92,799 22.631700
    8/30/2023 134,260 22.609400
    8/30/2023 53,702 22.592500
    8/30/2023 26,851 22.621500
    8/31/2023 80,556 22.603000
    8/31/2023 88,158 22.600000
    8/31/2023 88,923 22.599900
    9/1/2023 54 22.630000
    9/5/2023 13,514 22.819900
    9/5/2023 40,278 22.863300
    9/5/2023 26,852 22.817800
    9/5/2023 5,370 22.860700
    9/5/2023 5,370 22.859100
    9/5/2023 27,731 22.890300
    9/5/2023 26,852 22.850000
    9/6/2023 68,936 22.847200
    9/6/2023 53,704 22.816100
    9/6/2023 129,012 22.763400
    9/6/2023 26,852 22.849900
    9/6/2023 53,704 22.820200
    9/6/2023 26,852 22.789000
    9/6/2023 40,278 22.790600
    9/6/2023 10,741 22.830000

     

     

    CUSIP No. 000380204SCHEDULE 13DPage 21 of 22 Pages

     

     

    Trade Date

    ADSs Purchased

    (Sold)

    Price Per ADS ($)
    9/7/2023 45,526 22.850000
    9/7/2023 53,704 22.869600
    9/7/2023 67,130 22.879500
    9/7/2023 80,556 22.871600
    9/7/2023 26,852 22.859400
    9/7/2023 53,704 22.865000
    9/7/2023 40,278 22.860300
    9/7/2023 26,852 22.862800
    9/7/2023 8,645 22.830000
    9/8/2023 18,206 22.860000
    9/11/2023 26,851 22.800000
    9/11/2023 83,685 22.770900
    9/11/2023 147,720 22.784700
    9/11/2023 24,167 22.801700
    9/11/2023 13,426 22.789400
    9/12/2023 126,203 22.750000
    9/12/2023 26,851 22.730200
    9/12/2023 26,851 22.734800
    9/12/2023 10,740 22.717400
    9/13/2023 12,946 22.720000
    9/13/2023 53,704 22.691600
    9/13/2023 1,633 22.700000
    9/13/2023 983 22.710000
    9/15/2023 26,852 22.670000

     

     

     

    CUSIP No. 000380204SCHEDULE 13DPage 22 of 22 Pages

     

    Trade Date

    ADSs Purchased

    (Sold)

    Price Per ADS ($)
    9/15/2023 24,237 22.660700
    9/15/2023 37,593 22.652500
    9/15/2023 134,258 22.650000
    9/18/2023 26,852 22.640000
    9/18/2023 41,944 22.645800
    9/18/2023 13,426 22.654000
    9/18/2023 67,130 22.650000
    9/19/2023 11,758 22.639700
    10/4/2023 26,852 22.798800
    10/5/2023 80,556 22.829900
    10/6/2023 26,852 22.706100
    10/12/2023 1,270,093 22.741800
    10/12/2023 53,704 22.709000
    10/13/2023 80,556 22.700000
    10/13/2023 37,593 22.730000
    10/13/2023 26,852 22.690000
    10/13/2023 1,734,354 22.710000

     

     

    Get the next $ABCM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ABCM

    DatePrice TargetRatingAnalyst
    6/20/2023$23.00 → $22.00Outperform → Sector Perform
    RBC Capital Mkts
    6/16/2023$25.00Neutral → Buy
    BofA Securities
    12/14/2022$15.00Hold
    Deutsche Bank
    More analyst ratings

    $ABCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Abcam downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded Abcam from Outperform to Sector Perform and set a new price target of $22.00 from $23.00 previously

      6/20/23 7:17:42 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Abcam upgraded by BofA Securities with a new price target

      BofA Securities upgraded Abcam from Neutral to Buy and set a new price target of $25.00

      6/16/23 7:25:35 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Deutsche Bank initiated coverage on Abcam with a new price target

      Deutsche Bank initiated coverage of Abcam with a rating of Hold and set a new price target of $15.00

      12/14/22 7:33:18 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ABCM
    SEC Filings

    See more
    • SEC Form 15-12G filed by Abcam plc

      15-12G - Abcam plc (0001492074) (Filer)

      12/18/23 4:17:02 PM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Abcam plc

      S-8 POS - Abcam plc (0001492074) (Filer)

      12/15/23 4:24:56 PM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Abcam plc

      S-8 POS - Abcam plc (0001492074) (Filer)

      12/15/23 4:21:28 PM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ABCM
    Financials

    Live finance-specific insights

    See more
    • Jonathan Milner issues Open Letter to shareholders of Abcam plc

      Jonathan Milner issues Open Letter to shareholders of Abcam plc Urges shareholders to Vote AGAINST the proposed acquisition of Abcam by Danaher Corporation CAMBRIDGE, England, 28 September 2023 – Dr. Jonathan Milner, the founder and one of the largestinvestors in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.15%, todayissued an open letter to the Company's shareholders announcing his "Vote AGAINST" campaign and providing them with the opportunity to send a clear message to the Board that they are dissatisfied with the proposed acquisition of Abcam by Danaher Corporation (NYSE:DHR) or its affiliates ("Danaher") and Abcam's governance, execution and cost control.

      9/28/23 2:00:00 AM ET
      $ABCM
      $DHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Machinery/Components
      Industrials
    • Dr. Jonathan Milner opposes Danaher's acquisition of Abcam and calls for EGM to replace Board

      Dr. Jonathan Milner opposes Danaher's acquisition of Abcam and calls for EGM to replace Board CAMBRIDGE, England, 14 September 2023 – Dr. Jonathan Milner, the founder and one of the largest investors in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.14%, today announces his decision to vote against the proposed acquisition of Abcam by Danaher Corporation (NYSE:DHR) or its affiliates ("Danaher"). In addition to this, he will formally request the Abcam Board of Directors to convene a General Meeting ("EGM") with the purpose of replacing the Company's Board, including the current CEO, CFO and Chairman. Jonathan Milner's decision to oppose the acquisition is informed by e

      9/14/23 8:00:00 AM ET
      $ABCM
      $DHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Machinery/Components
      Industrials
    • Danaher to acquire Abcam for $24.00 per Share

      Abcam plc (NASDAQ:ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, announced today that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE:DHR) (‘Danaher') will acquire all of the outstanding shares of Abcam for $24.00 per share in cash (the ‘Transaction'). The Transaction has been unanimously approved and recommended by the Abcam Board of Directors and unanimously approved by the Danaher Board of Directors. Founded in 1998 and headquartered in Cambridge, UK, Abcam offers the scientific community highly validated antibodies, reagents, biomarkers and assays to address targets in biological pat

      8/28/23 7:35:00 AM ET
      $ABCM
      $DHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Machinery/Components
      Industrials

    $ABCM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Danaher Completes Acquisition of Abcam

      WASHINGTON, Dec. 6, 2023 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher") announced today it has completed its acquisition of Abcam plc (NASDAQ:ABCM) ("Abcam"). The acquisition of Abcam for $24.00 per share in cash was implemented by way of a Court-sanctioned scheme of arrangement under the UK Companies Act 2006 (the "Scheme") and the Scheme became effective in accordance with its terms on December 6, 2023. As a result, Abcam has become an indirect wholly owned subsidiary of Danaher. Trading of Abcam ADSs on Nasdaq has been suspended. The consideration due to former Abcam shareholders will be settled pursuant to the terms of the Scheme and the consideration due to former Abcam ADS

      12/6/23 7:30:00 AM ET
      $ABCM
      $DHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Machinery/Components
      Industrials
    • Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales

      Abcam plc (NASDAQ:ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE:DHR) (‘Danaher') for $24.00 per share in cash (the ‘Transaction'), to be implemented by way of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the ‘Scheme‘). The circular in relation to the Scheme was published or made available to Scheme Shareholders on October 5, 2023 (the ‘Scheme Circular‘). Abcam is pleased to announce that the Court has today issued the Court Order sanctioning the Scheme. Closing of the T

      12/4/23 4:01:00 PM ET
      $ABCM
      $DHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Machinery/Components
      Industrials
    • Abcam Acquisition by Danaher Has Received All Identified Clearances; Transaction Expected to Close on December 6, 2023

      Abcam plc (NASDAQ:ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, which entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE:DHR) (‘Danaher') for $24.00 per share in cash (the ‘Transaction'), today announced that all Identified Clearances required in connection with the Transaction have been obtained from the relevant Governmental Authorities. The Transaction remains subject to the sanction of the Scheme by the High Court of Justice of England and Wales and the satisfaction or waiver (if applicable) of certain other customary closing conditions as set out in Par

      11/17/23 7:00:00 AM ET
      $ABCM
      $DHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Machinery/Components
      Industrials

    $ABCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Abcam plc (Amendment)

      SC 13G/A - Abcam plc (0001492074) (Subject)

      2/12/24 5:24:03 PM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Abcam plc (Amendment)

      SC 13G/A - Abcam plc (0001492074) (Subject)

      1/12/24 11:40:16 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Abcam plc (Amendment)

      SC 13D/A - Abcam plc (0001492074) (Subject)

      12/8/23 4:30:10 PM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ABCM
    Leadership Updates

    Live Leadership Updates

    See more
    • Jonathan Milner issues Open Letter to shareholders of Abcam plc

      Jonathan Milner issues Open Letter to shareholders of Abcam plc Highlights Company's loss of focus on governance, execution and cost control leading to value destruction and a share price materially below where it should be Outlines Milner's plan to restore shareholder trust and value and make Abcam the world leading antibody company once again CAMBRIDGE, England, 12 June 2023 – Jonathan Milner, the founder and one of the largest investors in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.3% of the Company, has today issued an open letter to the Company's shareholders calling for the removal of Peter Allen, Michael S. Baldock and Sally W. Crawford as Directors of th

      6/12/23 7:00:00 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jonathan Milner Announces That He is Taking Steps to Call an Extraordinary General Meeting of Abcam Shareholders

      Jonathan Milner Announces That He is Taking Steps to Call an Extraordinary General Meeting of Abcam Shareholders Delivers Open Letter to Abcam shareholders Follows sustained period of operational underperformance since the start of 2020 and a track record of value destruction under the current Board and leadership team Critical for shareholders to have a platform to exert their right to restore focus for Abcam on governance, execution, and cost control to elevate it to the valuation it rightly deserves CAMBRIDGE, England, 17 May 2023 – Jonathan Milner, the founder and one of the largest investors in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.3% of the Company, a

      5/17/23 9:15:00 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Abcam: Appointment of Vice President of Investor Relations

      CAMBRIDGE, England, June 27, 2022 /PRNewswire/ -- Abcam plc ("Abcam," "Company," "Group") (AIM: ABC) (NASDAQ:ABCM), a global leader in the supply of life science research tools, today announces the appointment of Tommy Thomas as Vice President of Investor Relations.     Tommy, who will be based in our Waltham, MA office, has over 20 years' experience in the life sciences sector, largely focused in the area of research tools. He joins Abcam from Avantor, where he was Vice President, Investor Relations for several years. Prior to this he was Vice President of Investor Relations, and then Chief Financial Officer of Global Services at Perkin Elmer. Before joining Perkin Elmer, Tommy spent eight

      6/27/22 2:00:00 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care